The first five-year cumulative revenue (2017-2021) is projected to be US$ 1,946.0 Mn, which is expected to increase rather moderately over the latter part of the five-year forecast period. According to report, the glycated hemoglobin testing market is projected to reach a value of over US$ 650 Mn in 2026 at a CAGR of 8.6% over the forecast period.

Global Glycated Hemoglobin Testing Market: Segmental Snapshot

By test-type: The lab based test segment accounted for highest revenue share contribution as compared to that of the point-of-care test, and is expected to register a CAGR of 8.5% over the forecast period.

By technique: The chromatography segment is projected to account for highest revenue share among other technique segments, and register a CAGR of 8.6% over the forecast period.

By end user: Hospitals segment is estimated to account for highest revenue share among the end user segments, and is projected to register a CAGR of over 8.5% over the forecast period.

By region: The market in North America accounted for highest revenue share in the global glycated hemoglobin testing market in 2016, and is expected to record a CAGR of over 8.5% between 2017 and 2026.

Global Glycated Hemoglobin Testing Market: Competitive Analysis

The research report on the Global Glycated Hemoglobin Testing Market includes profiles of some of major companies such as Abbott Laboratories, Alere, Inc., Danaher Corp., F. Hoffmann-La Roche AG, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., ARKRAY, Inc., Bayer AG, Tosoh Corporation, and Siemens AG.

Source of Infographics: Glycated Hemoglobin Testing Market Infographics by MarketResearch